Stock Events

Stock Events

ImmunityBio 

$7.14
376
-$0.53-6.91% Wednesday 20:00

Statistics

Day High
7.85
Day Low
7.01
52W High
12.43
52W Low
1.83
Volume
19,213,410
Avg. Volume
39,125,826
Mkt Cap
7.34B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.2
-0.15
-0.11
-0.06
Expected EPS
-0.07046
Actual EPS
N/A

Financials

-310.18%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
226.58MRevenue
-702.8MNet Income

Analyst Ratings

$13.40Average Price Target
The highest estimate is 23.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IBRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, directly competing in the development of vaccines and therapeutics, areas where ImmunityBio is also active.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech, similar to Moderna, specializes in mRNA technology for developing vaccines, including for COVID-19, competing with ImmunityBio's efforts in vaccine development.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a competitor in the vaccine space, particularly for COVID-19, where ImmunityBio also aims to make an impact.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company with a broad portfolio that includes vaccines and cancer treatments, areas where ImmunityBio is also involved.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and oncology treatments, overlapping with ImmunityBio's focus areas.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in developing vaccines and treatments for various diseases, including cancer, directly competing with ImmunityBio's research and development efforts.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that focuses on antiviral drugs and cancer therapies, competing with ImmunityBio in the oncology and infectious disease sectors.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including oncology and cardiovascular diseases, areas where ImmunityBio is also seeking to make advancements.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its work in immunology and oncology, directly competing with ImmunityBio's efforts in developing immune-based therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that operates in various therapeutic areas, including oncology and vaccines, making it a competitor to ImmunityBio.

About

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Show more...
CEO
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.Sc.
Employees
671
Country
US
ISIN
US45256X1037

Listings

F
DE
26CA.F
BOATS
BOATS
IBRX.BOATS
XNAS
US
IBRX

0 Comments

Share your thoughts

FAQ

What is ImmunityBio stock price today?▼
The current price of IBRX is $7.14 USD — it has decreased by -6.91% in the past 24 hours. Watch ImmunityBio stock price performance more closely on the chart.
What is ImmunityBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ImmunityBio stocks are traded under the ticker IBRX.
Is ImmunityBio stock price growing?▼
IBRX stock has fallen by -3.25% compared to the previous week, the month change is a -31.61% fall, over the last year ImmunityBio has showed a +134.1% increase.
What is ImmunityBio market cap?▼
Today ImmunityBio has the market capitalization of 7.34B
When is the next ImmunityBio earnings date?▼
ImmunityBio is going to release the next earnings report on May 07, 2026.
What were ImmunityBio earnings last quarter?▼
IBRX earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.08 USD resulting in a +21.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ImmunityBio revenue for the last year?▼
ImmunityBio revenue for the last year amounts to 226.58M USD.
What is ImmunityBio net income for the last year?▼
IBRX net income for the last year is -702.8M USD.
How many employees does ImmunityBio have?▼
As of April 02, 2026, the company has 671 employees.
In which sector is ImmunityBio located?▼
ImmunityBio operates in the Health Care sector.
When did ImmunityBio complete a stock split?▼
ImmunityBio has not had any recent stock splits.
Where is ImmunityBio headquartered?▼
ImmunityBio is headquartered in San Diego, US.